Nama's AI scorecard currently rates Ventas Hold (5.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is VTR's P/E ratio?

Ventas trades at a trailing price-to-earnings ratio of 164.3.

When does VTR report earnings?

Ventas's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $0.12.

What is the VTR price target?

The median analyst price target from 22 analysts is $98.50, with a range of $90.00 – $112.00.

Is VTR Shariah compliant?

Nama's AAOIFI-style screen reads Ventas as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Does VTR pay a dividend?

Yes — Ventas's dividend yield is 2.3%.

Nama Insights

Ventas (VTR)

Real Estate · Reit Healthcare Facilities · NYSE

S&P 500

Ventas (VTR) is a Real Estate company in the Reit Healthcare Facilities industry. It has a market capitalization of $46.93B, a trailing price-to-earnings ratio of 164.3 and a free-cash-flow yield of 2.5%. Over the most recent reported fiscal year, revenue grew 18.5% and free cash flow per share grew 24.3%. Nama's AI scorecard rates it Hold, 5.3 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Hold · 5.3/10

The sections balance. As of Nov 7, 2026.

Momentum

Middle · +6.8% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-12.7%

How far the last close sits under the highest price of the past five years.

Market cap	$46.93B
Trailing P/E	164.3
Price / book	3.0
Price / sales	7.0
FCF yield	2.5%
Dividend yield	2.3%
Gross margin	39.7%
Operating margin	13.4%
Net margin	3.9%
Revenue growth (YoY)	+18.5%
Revenue growth (3-yr annual)	+12.2%
EPS growth (YoY)	+194.1%
FCF/share growth (YoY)	+24.3%
Beta	0.7
Exchange	NYSE
Sector	Real Estate
Industry	Reit Healthcare Facilities

VTR earnings

Next report: Feb 3, 2027 (Q4 2026, EPS estimate $0.12). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 27, 2026	$0.14	$0.11	+27.3%	$1.83B
Q2 2026	Jul 29, 2026	$0.17	$0.11	+54.5%	$1.73B
Q1 2026	Apr 27, 2026	$0.10	$0.10	+0.0%	$1.66B
Q4 2025	Feb 5, 2026	$0.13	$0.09	+44.4%	$1.57B

VTR analyst price target

Median target $98.50 from 22 analysts, ranging $90.00 – $112.00.

Reit Healthcare Facilities peers

Ticker	Company	Market cap	P/E
WELL	Welltower	$179.74B	106.1
OHI	Omega Healthcare Investors	$15.34B	17.6
DOC	Healthpeak Properties	$14.71B	40.5
AHR	American Healthcare REIT	$12.62B	103.4
CTRE	CareTrust REIT	$9.03B	25.1
HR	Healthcare Realty Trust	$6.66B	—
SBRA	Sabra Health Care REIT	$5.51B	31.9
NHI	National Health Investors	$3.50B	21.1

Explore live VTR data on Nama Insights →

Recent Congressional trades

Ventas trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Earl Blumenauer	House	Sell	$15,001 - $50,000	Oct 8, 2024
Daniel Goldman	House	Sell	$1,001 - $15,000	Aug 13, 2023
Kelly Loeffler	Senate	Sell	$100,001 - $250,000	—
Patty Murray	Senate	Sell	$1,001 - $15,000	—

VTR FAQ

Is VTR a buy?: Nama's AI scorecard currently rates Ventas Hold (5.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is VTR's P/E ratio?: Ventas trades at a trailing price-to-earnings ratio of 164.3.
When does VTR report earnings?: Ventas's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $0.12.
What is the VTR price target?: The median analyst price target from 22 analysts is $98.50, with a range of $90.00 – $112.00.
Is VTR Shariah compliant?: Nama's AAOIFI-style screen reads Ventas as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does VTR pay a dividend?: Yes — Ventas's dividend yield is 2.3%.